期刊
JOURNAL OF VASCULAR RESEARCH
卷 51, 期 2, 页码 102-109出版社
KARGER
DOI: 10.1159/000357620
关键词
Vascular accessory cells; Antiangiogenic treatment; Sunitinib
资金
- Volkswagen Foundation
- Charlie Foundation
Objective: Antiangiogenic therapies could be limited by various escape mechanisms including bone marrow-derived myeloid cell-induced vasculogenesis. The recruitment of vascular accessory cells (VACs) to the tumor neovasculature is as a multistep process. However, the recruitment process of these cells during antiangiogenic treatment remains unknown. The aim of our study was to characterize the recruitment of VACs during antiangiogenic therapy using sunitinib. Methods: C6 glionna cells were implanted into dorsal skinfold chambers. Animals received antiangiogenic therapy intraperitoneally for 5 days prior to VAC application intra-arterially. Intravital microscopy was performed during VAC injection and 1 and 48 h after injection. Analyses included total (TVD) and functional vessel densities (FVD), the perfusion index (PI), microvascular permeability, blood flow rate (Q), nnicrovascular diameter (D), red blood cell velocity (RBCV), wall shear rate (gamma), wall shear stress (tau), first and firm adhesions of VACs, and accumulation in the perivascular niche. Results: Antiangiogenic therapy resulted in a significant reduction in TVD (365 +/- 47 cm/cm(2) vs. 183 +/- 37 cm/cm(2)) and FVD (227 +/- 65 cm/cm(2) vs. 147 +/- 25 cm/cm(2)) and an increase in PI, Q, D, and RBCV. gamma and tau remained unaltered. Initial adhesion and firm adhesion were unaffected by antiangiogenic therapy; however, the accumulation in the perivascular niche was significantly diminished in treated tumors (53.7 +/- 8% vs. 24.0 +/- 17%). Conclusions: Antiangiogenic treatment inhibits the accumulation of VACs in the perivascular niche and therefore interferes with consecutive neovascularization. (C) 2014 S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据